Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHa, Jasonen
dc.contributor.authorChurilov, Leoniden
dc.contributor.authorLinden, Thomasen
dc.contributor.authorBernhardt, Julieen
dc.identifier.citationInternational Journal of Stroke 2011; 8(3): 172-9en
dc.description.abstractAcute stroke management is a dynamic field. Treatment with recombinant tissue plasminogen activator is standard care in Australia, but there are no evidence-based practice guidelines about first out of bed activity (mobilization) after recombinant tissue plasminogen activator.To identify factors influencing clinicians' decisions to delay or allow mobilization.Case-crossover design. Using hypothetical case vignettes, we explored the factors that clinicians consider when deciding to first mobilize a patient after recombinant tissue plasminogen activator. Acute stroke physicians and nurses from Australian hospitals known to treat with recombinant tissue plasminogen activator participated. Information about hospital recombinant tissue plasminogen activator protocols and perceived benefits and harms of mobilization after recombinant tissue plasminogen activator were also captured.Fifty-four clinicians, 52% senior nurses, and 48% senior physicians from all states of Australia participated. Of the factors influencing decisions about mobilization after recombinant tissue plasminogen activator, neurological decline (0.29; confidence interval 0.12, 0.46; P = 0.001), neurological decline with symptomatic intracerebral hemorrhage (0.41; confidence interval 0.24, 0.59; P < 0.0001), infection of uncertain cause (0.32; confidence interval 0.14, 0.50; P = 0.001), severe chest infection (0.35; confidence interval 0.16, 0.53; P = 0.0004), severe stroke (0.29; confidence interval 0.12, 0.46; P = 0.001), drowsiness (0.47; confidence interval 0.29, 0.63; P < 0.0001), and confusion (0.31; confidence interval 0.15, 0.47; P = 0.0001) significantly influenced decisions. Falls risk was a common concern (85%).Growing interest in development of clear protocols that guide first mobilization after recombinant tissue plasminogen activator prompted this study. We have identified factors that may influence decisions about when to allow patients to mobilize after recombinant tissue plasminogen activator. These, combined with emerging evidence of risks and benefits of early mobilization, should help protocol development in the future.en
dc.subject.otherBed Resten
dc.subject.otherClinical Protocolsen
dc.subject.otherCombined Modality Therapyen
dc.subject.otherCross-Over Studiesen
dc.subject.otherDecision Makingen
dc.subject.otherEarly Ambulationen
dc.subject.otherFibrinolytic Agents.therapeutic useen
dc.subject.otherPilot Projectsen
dc.subject.otherProfessional Practiceen
dc.subject.otherRecombinant Proteins.therapeutic useen
dc.subject.otherTissue Plasminogen Activator.therapeutic useen
dc.subject.otherTreatment Outcomeen
dc.titleBed rest or mobilization after rt-PA? A case-crossover study of factors influencing clinical decision making in stroke services.en
dc.typeJournal Articleen
dc.identifier.journaltitleInternational Journal of Strokeen
dc.identifier.affiliationFlorey Neuroscience Institutes, Austin Campus, Heidelberg, Victoria, Australiaen
dc.type.austinJournal Articleen
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.languageiso639-1en- (University of Melbourne)- Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jan 30, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.